News | May 11, 2022
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
The ultrasound products manufactured in the new manufacturing facility will be sold under the brand name SonoRad, and are designed for large hospitals, healthcare institutions and individual radiology centres
Subscribe To Our Newsletter & Stay Updated
